Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Capital Expenditures for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 434.95% year-over-year to $1.5 million, compared with a TTM value of $1.6 million through Dec 2025, down 19.68%, and an annual FY2025 reading of $1.6 million, down 19.68% over the prior year.
  • Capital Expenditures was $1.5 million for Q4 2025 at Keros Therapeutics, up from -$1.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.5 million in Q4 2025 and bottomed at -$1.3 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $352555.6, with a median of $368500.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures skyrocketed 2783.33% in 2021, then crashed 477.21% in 2023.
  • Year by year, Capital Expenditures stood at $159000.0 in 2021, then skyrocketed by 120.75% to $351000.0 in 2022, then plummeted by 477.21% to -$1.3 million in 2023, then surged by 121.83% to $289000.0 in 2024, then skyrocketed by 434.95% to $1.5 million in 2025.
  • Business Quant data shows Capital Expenditures for KROS at $1.5 million in Q4 2025, -$1.3 million in Q3 2025, and $720000.0 in Q2 2025.